Who are Vaccination with Gardasil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comparator: Gardasil, Gardasil as three dose regimen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vaccination-with-gardasil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vaccination with Gardasil — Competitive Intelligence Brief

Vaccination with Gardasil (Vaccination with Gardasil) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant quadrivalent HPV vaccine. Area: Oncology / Immunology / Infectious Disease.

phase 3 Recombinant quadrivalent HPV vaccine Human papillomavirus (HPV) types 6, 11, 16, 18 Oncology / Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Vaccination with Gardasil (Vaccination with Gardasil) — Assistance Publique - Hôpitaux de Paris. Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vaccination with Gardasil TARGET	Vaccination with Gardasil	Assistance Publique - Hôpitaux de Paris	phase 3	Recombinant quadrivalent HPV vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18
Comparator: Gardasil	Comparator: Gardasil	Merck Sharp & Dohme LLC	phase 3	Recombinant quadrivalent HPV vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18
Gardasil as three dose regimen	Gardasil as three dose regimen	Serum Institute of India Pvt. Ltd.	phase 3	Recombinant quadrivalent HPV vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18 L1 capsid protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant quadrivalent HPV vaccine class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Serum Institute of India Pvt. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vaccination with Gardasil — Competitive Intelligence Brief. https://druglandscape.com/ci/vaccination-with-gardasil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab